Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Talha Munir

Talha Munir

MBBS
Leeds Teaching Hospitals NHS Trust

Talha Munir, MBBS, is a consultant hematologist at Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Dr Munir has clinical and research interests in chronic lymphocytic leukemia (CLL), particularly in the assessment of the mechanisms of action of novel targeted therapies for CLL.

55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL 1:35
55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL
Talha Munir • 12 Dec 2023
MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL 1:21
MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL
Talha Munir • 12 Dec 2023
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL 2:17
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL
Talha Munir • 11 Dec 2023
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL 1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023
Managing cardiac toxicities associated with BTK inhibitors and selecting between these agents 1:06
Managing cardiac toxicities associated with BTK inhibitors and selecting between these agents
Talha Munir • 24 Apr 2023
Long-term safety and efficacy of eculizumab and ravulizumab in patients with PNH 1:07
Long-term safety and efficacy of eculizumab and ravulizumab in patients with PNH
Talha Munir • 24 Apr 2023
Final analysis of the ALPINE trial: zanubrutinib vs ibrutinib in R/R CLL 1:05
Final analysis of the ALPINE trial: zanubrutinib vs ibrutinib in R/R CLL
Talha Munir • 24 Apr 2023
Safety and efficacy of pirtobrutinib in patients with R/R B-cell malignancies 0:57
Safety and efficacy of pirtobrutinib in patients with R/R B-cell malignancies
Talha Munir • 24 Apr 2023
Factors to consider when selecting between continuous and fixed-duration therapy in CLL 1:13
Factors to consider when selecting between continuous and fixed-duration therapy in CLL
Talha Munir • 24 Apr 2023
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL 1:23
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
Talha Munir • 12 Dec 2022
The current role of MRD in CLL and future outlooks 0:48
The current role of MRD in CLL and future outlooks
Talha Munir • 12 Dec 2022
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL 1:17
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
Talha Munir • 12 Dec 2022
MRD: a prognostic marker in targeted therapy 3:45
MRD: a prognostic marker in targeted therapy
Talha Munir • 21 Sep 2019
Young Investigator Meeting at iwCLL 2019 2:00
Young Investigator Meeting at iwCLL 2019
Talha Munir • 21 Sep 2019
Improved MRD response rates in CLL with obinutuzumab after ibrutinib exposure 1:38
Improved MRD response rates in CLL with obinutuzumab after ibrutinib exposure
Talha Munir • 1 Apr 2019
Lessons learned from the CLL CLARITY study and ongoing follow-up 1:44
Lessons learned from the CLL CLARITY study and ongoing follow-up
Talha Munir • 1 Apr 2019
The content of VJHemOnc is intended for healthcare professionals